Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.
about
Determination of Phenotypic Resistance Cutoffs From Routine Clinical DataCross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations.A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences.Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis.Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failureResidual activity of two HIV antiretroviral regimens prescribed without virological monitoringNovel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antDevelopment and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
P2860
Q31139379-EAC4E873-FCF8-45D8-81F2-6428504091ABQ34038440-AF116A44-A7C7-4559-B2D9-2DF5BB506C1DQ34321402-8BCE2A05-15B3-4360-B1FB-383DA69B0A0FQ34457230-2FC39C12-22B4-4A26-9A7C-7DCE39AEBF3DQ34681252-BA0550D9-318B-410B-96A7-0F2995FC56E5Q34781706-C5259D61-224F-426F-B297-D6A1F7EC307CQ35270968-7BE4C0A0-681B-4676-B194-8ED6B273AFD7Q42148219-8D1DC46A-703E-42FB-8F4C-4D3C809F9CECQ44541542-5020D935-2088-407C-AB38-F2024DB26DE6
P2860
Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clinical cut-offs for HIV-1 ph ...... ed approach to viral mixtures.
@ast
Clinical cut-offs for HIV-1 ph ...... ed approach to viral mixtures.
@en
type
label
Clinical cut-offs for HIV-1 ph ...... ed approach to viral mixtures.
@ast
Clinical cut-offs for HIV-1 ph ...... ed approach to viral mixtures.
@en
prefLabel
Clinical cut-offs for HIV-1 ph ...... ed approach to viral mixtures.
@ast
Clinical cut-offs for HIV-1 ph ...... ed approach to viral mixtures.
@en
P2093
P1476
Clinical cut-offs for HIV-1 ph ...... ed approach to viral mixtures.
@en
P2093
Bart Winters
Jorge Villacian
Koen Van der Borght
Lee Bacheler
Pierre Lecocq
P304
P356
10.1016/J.JVIROMET.2009.07.023
P577
2009-08-03T00:00:00Z